Forte Biosciences, Inc.
NASDAQ:FBRX · NASDAQ Capital Market
+$0.16 today
Vol 0.17M · Avg 0.30M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $58.2M |
| Receivables | $655.0K |
| Other Current | $6.2M |
| Total Current Assets | $65.1M |
| PP&E (Net) | $110.0K |
| Other Non-current | $2.0M |
| Total Non-current Assets | $2.1M |
| Total Assets | $67.2M |
Analysis
Selected assets total $67.2M for Latest. The largest visible component is Cash & Equivalents at $58.2M, about 86.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.0M +246.0% | $22.2M +86.0% | $12.0M -70.9% | $41.1M -2.2% | $42.0M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 -100.0% | $36.1M +43.5% | $25.2M | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $817.0K | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $422.0K +25.6% | $336.0K +103.6% | $165.0K +135.7% | $70.0K -21.3% | $89.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $80.6M +31.4% | $61.3M +60.1% | $38.3M -7.7% | $41.5M -2.4% | $42.5M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $129.0K +67.5% | $77.0K -29.4% | $109.0K | $0 | $0 | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $2.1M +1393.5% | $138.0K -74.6% | $544.0K +11.9% | $486.0K -38.2% | $786.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $2.2M +918.6% | $215.0K -67.1% | $653.0K +34.4% | $486.0K -38.2% | $786.0K | -$15.3B | $14.8B | $11.3B |
| Total Assets | $82.8M +34.5% | $61.6M +57.9% | $39.0M -7.2% | $42.0M -3.0% | $43.3M | $13.3B | $11.9B | $10.6B |
| Account Payables | $10.0M +104.7% | $4.9M +242.6% | $1.4M +23.5% | $1.2M +21.9% | $946.0K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $1.0M | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $2.3M +45.1% | $1.6M +63.8% | $947.0K +6.4% | $890.0K +30.7% | $681.0K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $20.8M +128.5% | $9.1M +147.7% | $3.7M +15.3% | $3.2M +80.8% | $1.8M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $1.0M | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $1.0M | $0 | $0 | $0 | $0 | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $21.8M +139.9% | $9.1M +147.7% | $3.7M +15.3% | $3.2M +80.8% | $1.8M | $14.7B | $3.7B | $9.6B |
| Common Stock | $13.0K +116.7% | $6.0K -83.3% | $36.0K +71.4% | $21.0K +40.0% | $15.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$223.4M -45.0% | -$154.0M -29.9% | -$118.5M -36.2% | -$87.0M -19.0% | -$73.2M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $3.0K -72.7% | $11.0K +175.0% | $4.0K | $0 +100.0% | -$43.3M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $61.0M +16.2% | $52.5M +48.6% | $35.3M -9.0% | $38.8M -6.6% | $41.5M | $9.1B | $7.7B | $3.3B |
| Total Debt | $0 | $0 | $0 | $0 | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | -$77.0M -246.0% | -$22.2M -86.0% | -$12.0M +70.9% | -$41.1M +2.2% | -$42.0M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Actuate Therapeutics Inc
ACTU
$48.33M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does FBRX have?
Forte Biosciences, Inc. (FBRX) reported $76.96M in cash and equivalents in fiscal 2025.
How much debt does FBRX carry?
Forte Biosciences, Inc. (FBRX) reported $0.00 of total debt, with net debt of -$76,957,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.